Titan Pharmaceuticals, Inc. (TTNP) P/E Ratio History
Historical price-to-earnings valuation from 1997 to 2017
Loading P/E history...
TTNP Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Titan Pharmaceuticals, Inc. (TTNP) trades at a price-to-earnings ratio of -0.6x, with a stock price of $3.08 and trailing twelve-month earnings per share of $-2.63.
The current P/E is 100% below its 5-year average of 966.4x. Over the past five years, TTNP's P/E has ranged from a low of 106.5x to a high of 7528.8x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, TTNP trades at a 103% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, TTNP trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our TTNP DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
TTNP P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $321M | 35.7 | - | -43% | |
| $1B | 22.7Lowest | 1.27Best | -7% | |
| $1B | 177.5 | - | -79% | |
| $358B | 85.5 | - | -1% | |
| $2B | 36.3 | 4.85 | +1883%Best | |
| $930M | 147.8 | - | +107% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
TTNP Historical P/E Data (1997–2017)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2017 Q1 | Fri Mar 31 2017 00:00:00 GM | $11880.00 | $31.85 | 373.0x | -61% |
| FY2016 Q4 | Sat Dec 31 2016 00:00:00 GM | $14400.00 | $40.86 | 352.4x | -64% |
| FY2016 Q3 | Fri Sep 30 2016 00:00:00 GM | $21168.00 | $40.22 | 526.3x | -46% |
| FY2016 Q2 | $19692.00 | $46.26 | 425.7x | -56% | |
| FY2014 Q1 | Mon Mar 31 2014 00:00:00 GM | $13325.97 | $24.59 | 541.9x | -44% |
| FY2013 Q4 | $12132.60 | $113.97 | 106.5x | -89% | |
| FY2013 Q3 | Mon Sep 30 2013 00:00:00 GM | $13325.97 | $113.12 | 117.8x | -88% |
| FY2013 Q2 | Sun Jun 30 2013 00:00:00 GM | $9149.17 | $8.16 | 1121.2x | +16% |
| FY1998 Q3 | Wed Sep 30 1998 00:00:00 GM | $60911.60 | $440.55 | 138.3x | -86% |
| FY1998 Q2 | $91988.95 | $361.35 | 254.6x | -74% | |
| FY1998 Q1 | $93232.05 | $846.45 | 110.1x | -89% | |
| FY1997 Q4 | Wed Dec 31 1997 00:00:00 GM | $111878.45 | $14.86 | 7528.8x | +679% |
Average P/E for displayed period: 966.4x
See TTNP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs TTNP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare TTNP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonTTNP — Frequently Asked Questions
Quick answers to the most common questions about buying TTNP stock.
Is TTNP stock overvalued or undervalued?
TTNP trades at -0.6x P/E, below its 5-year average of 966.4x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does TTNP's valuation compare to peers?
Titan Pharmaceuticals, Inc. P/E of -0.6x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is TTNP's PEG ratio?
TTNP PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 1997-2017.